These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 36258237)
41. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Sitbon O; Bosch J; Cottreel E; Csonka D; de Groote P; Hoeper MM; Kim NH; Martin N; Savale L; Krowka M Lancet Respir Med; 2019 Jul; 7(7):594-604. PubMed ID: 31178422 [TBL] [Abstract][Full Text] [Related]
42. Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart Disease. Herbert S; Gin-Sing W; Howard L; Tulloh RMR Heart Lung Circ; 2017 Oct; 26(10):1113-1116. PubMed ID: 28237536 [TBL] [Abstract][Full Text] [Related]
43. New Drugs, Therapeutic Strategies, and Future Direction for the Treatment of Pulmonary Arterial Hypertension. Mercurio V; Bianco A; Campi G; Cuomo A; Diab N; Mancini A; Parrella P; Petretta M; Hassoun PM; Bonaduce D Curr Med Chem; 2019; 26(16):2844-2864. PubMed ID: 29421995 [TBL] [Abstract][Full Text] [Related]
44. Safety and feasibility audit of a home-based drug-transitioning approach for patients with pulmonary arterial hypertension: an observational study. Dawson A; Reddecliffe S; Coghlan C; Schreiber BE; Coghlan JG Eur J Cardiovasc Nurs; 2018 Oct; 17(7):612-618. PubMed ID: 29641223 [TBL] [Abstract][Full Text] [Related]
45. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis. Zhao Q; Guo N; Chen J; Parks D; Tian Z J Clin Pharm Ther; 2022 Feb; 47(2):146-156. PubMed ID: 34319626 [TBL] [Abstract][Full Text] [Related]
46. Combination Therapy of Pulmonary Arterial Hypertension with Vardenafil and Macitentan Assessed in a Human Ex Vivo Model. Hoenicka M; Golovchenko S; Englert L; Spaeth M; Shoshiashvili L; Großer C; Hofmann HS; Ried M Cardiovasc Drugs Ther; 2019 Jun; 33(3):287-295. PubMed ID: 30826900 [TBL] [Abstract][Full Text] [Related]
47. [Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension]. Moiseeva OM; Rudakova AV Ter Arkh; 2017; 89(3):72-77. PubMed ID: 28378734 [TBL] [Abstract][Full Text] [Related]
48. Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension. Tanaka S; Uchida S; Hakamata A; Miyakawa S; Odagiri K; Inui N; Watanabe H; Namiki N Pharmazie; 2020 Jun; 75(6):236-239. PubMed ID: 32539916 [TBL] [Abstract][Full Text] [Related]
50. The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross-species comparison of its cytochrome P450 induction pattern. Treiber A; Delahaye S; Seeland S; Gnerre C Pharmacol Res Perspect; 2020 Aug; 8(4):e00619. PubMed ID: 32613761 [TBL] [Abstract][Full Text] [Related]
51. Macitentan: A Review in Pulmonary Arterial Hypertension. Keating GM Am J Cardiovasc Drugs; 2016 Dec; 16(6):453-460. PubMed ID: 27580996 [TBL] [Abstract][Full Text] [Related]
52. Association of CYP2C9*2 with bosentan-induced liver injury. Markova SM; De Marco T; Bendjilali N; Kobashigawa EA; Mefford J; Sodhi J; Le H; Zhang C; Halladay J; Rettie AE; Khojasteh C; McGlothlin D; Wu AH; Hsueh WC; Witte JS; Schwartz JB; Kroetz DL Clin Pharmacol Ther; 2013 Dec; 94(6):678-86. PubMed ID: 23863877 [TBL] [Abstract][Full Text] [Related]
53. Macitentan for the treatment of pulmonary arterial hypertension. DuBrock HM; Channick RN Expert Rev Respir Med; 2014 Aug; 8(4):393-9. PubMed ID: 24998329 [TBL] [Abstract][Full Text] [Related]
54. Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis. Duo-Ji MM; Long ZW Int J Cardiol; 2017 May; 234():90-98. PubMed ID: 28233631 [TBL] [Abstract][Full Text] [Related]
55. Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension. Iglarz M; Landskroner K; Bauer Y; Vercauteren M; Rey M; Renault B; Studer R; Vezzali E; Freti D; Hadana H; Schläpfer M; Cattaneo C; Bortolamiol C; Weber E; Whitby BR; Delahaye S; Wanner D; Steiner P; Nayler O; Hess P; Clozel M J Cardiovasc Pharmacol; 2015 Nov; 66(5):457-67. PubMed ID: 26230396 [TBL] [Abstract][Full Text] [Related]
56. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension. Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826 [TBL] [Abstract][Full Text] [Related]
57. Systematic Review of Randomized Controlled Trials of Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension. Kuntz M; Leiva-Juarez MM; Luthra S Lung; 2016 Oct; 194(5):723-32. PubMed ID: 27506903 [TBL] [Abstract][Full Text] [Related]
58. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis. Dranitsaris G; Mehta S Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194 [TBL] [Abstract][Full Text] [Related]